SEQIRUS is undertaking a product defect correction after one batch of Palexia 100mg sustained-released (SR) tapentadol tablets, which are used to manage moderate to severe chronic pain, was found to have a labelling error.
The default, which is not apparent until the carton is opened, affects the blister strips in some packages from batch 985P01, which contain either faded or missing printed product details (pictured).
The absence of product and batch/expiry details "compromises the identity of the product", creating the risk of product mix-up and overdose.
The affected batch, which was distributed to medical wholesalers and distributors between 12 Nov 2019 and 15 Jan 2020, has been recalled from wholesalers by the Therapeutic Goods Administration (TGA) as a "precautionary measure".
Pharmacists are advised to check the individual blister strips from batch 985P01 before dispensing, and to ensure relevant staff and clients are aware of the issue.
For more info, call Seqirus Customer Service on 1800 008 275.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Feb 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Feb 20